The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 13, 2011
Filed:
Jul. 05, 2005
Maria Del Carmen Abrahantes Pérez, Ciudad de la Habana, CU;
Jesús Reyes González, Ciudad de la Habana, CU;
Gloria Véliz Rios, Cuidad de la Habana, CU;
Eduardo Martinez Diaz, Ciudad de la Habana, CU;
Caridad Anais Gasmuri González, Ciudad de la Habana, CU;
José Garcia Suárez, Ciudad de la Habana, CU;
Mónica Bequet Romero, Ciudad de la Habana, CU;
Luis Javier González López, Ciudad de la Habana, CU;
Lila Rosa Castellanos Serra, Ciudad de la Habana, CU;
Manuel Selman-housein Sosa, Ciudad de la Habana, CU;
Raúl Gómez Riera, Ciudad de la Habana, CU;
Jorge Victor Gavilondo Cowley, Ciudad de la Habana, CU;
Maria del Carmen Abrahantes Pérez, Ciudad de la Habana, CU;
Jesús Reyes González, Ciudad de la Habana, CU;
Gloria Véliz Rios, Cuidad de la Habana, CU;
Eduardo Martinez Diaz, Ciudad de la Habana, CU;
Caridad Anais Gasmuri González, Ciudad de la Habana, CU;
José Garcia Suárez, Ciudad de la Habana, CU;
Mónica Bequet Romero, Ciudad de la Habana, CU;
Luis Javier González López, Ciudad de la Habana, CU;
Lila Rosa Castellanos Serra, Ciudad de la Habana, CU;
Manuel Selman-Housein Sosa, Ciudad de la Habana, CU;
Raúl Gómez Riera, Ciudad de la Habana, CU;
Jorge Victor Gavilondo Cowley, Ciudad de la Habana, CU;
Centro De Ingenieria Genetica Y Biotecnologia, Cuidad de La Habana, CU;
Abstract
The present invention is related to a composition capable of inhibiting the growth of tumoral cells of different histological origins and of activated endothelial cells. The components of said compositions are polypeptide fragments of the serralisins, corresponding to the C-terminal fragment, from the internal metionine trough the end of the molecule, which could be combined among them and optionally with the prodigiosins that potentiate the antitumoral effect of the composition. The prodigiosins in the composition could be at a concentration of 0.1-100 nM. The anti-proliferative action of this composition is mediated by apoptotic mechanism. It's 'in vivo' administration has antitumoral, antiangiogenic and protective effect against malignant tumors.